Curtis Ruegg BS, PhD

Curtis Ruegg is a Chief Development Officer and Chief Operating Officer at the Parvus Therapeutics, Inc. Prior to joining NaNotics, Dr. Ruegg served as CEO at Amphivena Therapeutics, developing new therapeutics for cancer patients using their novel T cell engager platform, and as CEO of Parvus Therapeutics developing a novel nanomedicine platform targeting T-reg cells for autoimmune and inflammatory diseases. Prior to that, he served as Executive VP, Technical Operations at Revance Therapeutics where he established and managed the biologics development program, and built and oversaw GMP manufacturing and R&D facilities from IND through Phase 3. Previously, he was Senior VP, Technical Operations at Cotherix, supporting the NDA filing and expediting FDA review and approval for VENTAVIS, a drug/ device combination. Dr. Ruegg also served in leadership roles at AP Cells where he lead the development of a nanomedicine-based immunotherapeutic platform for the treatment of cancer and built and managed a GMP manufacturing facility. He began his career at Dendreon as a co-Inventor of Provenge for the treatment of prostate cancer. Dr. Ruegg received his Ph.D. from Johns Hopkins University School of Medicine pursuing research on retroviral-mediated immunosuppression and was a Cancer Research Institute Fellow at Stanford University School of Medicine working on novel immune cell surface receptors for therapeutic development.